Teleflex at Jefferies Global Healthcare Conference: focus shifts to integration
Teleflex, a healthcare company, attended the Jefferies Global Healthcare Conference to present its integration plan. CEO Jason Weidman discussed the company's progress and challenges in restructuring. Teleflex has completed its original equipment manufacturer (OEM) divestiture and anticipates the sale of its remaining acute care and interventional urology units to close by the end of 2026 or early 2027.
The company has utilized $600 million of its $1 billion share buyback program and reduced $700 million of debt. The integration of BIOTRONIK VI is advancing, with order routing errors in Europe reduced to under 1% and sales hiring gaps narrowed significantly. Management considers the interventional business a growth engine, thanks to a broader product range and new devices like Freesolve and EZPLAZ.
Weidman outlined a three-part strategy: complete divestitures, integrate BIOTRONIK VI, and simplify operations. Once the transformation stabilizes, Teleflex aims to raise its growth profile. The financial aspect of the transformation is advancing as planned, with the OEM business sale generating about three-quarters of total divestiture proceeds.
The company has deployed $600 million of its $1 billion share repurchase plan and retired $700 million of debt, maintaining leverage below 2.0x in the near term. In 2027, Teleflex anticipates a pro forma operating margin of around 23% post-final divestiture closure, reflecting the rollout of transition services and cost-cutting programs.
The company expects gross margins to settle in the low 60% range, slightly below the earlier mid-60% target due to tariffs. Management expects a meaningful earnings lift in 2027 as divestitures, cost cuts, and lower interest expenses flow through results. Weidman highlighted Teleflex's strong market positions, market-leading categories, and engaged workforce.
The interventional business, strengthened by the BIOTRONIK VI deal, now offers a complete treatment solution. Teleflex remains committed to a strong 2027 performance, focusing on stabilization before pursuing growth. The company envisions market share gains in treatment devices and international expansion opportunities. Long-term growth drivers include Freesolve, an absorbable metal stent, and Freesolve, being tested against drug-eluting stents.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.